GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - Leerink
June 28, 2016 7:58 AM EDT
Morgan Stanley maintained an Overweight rating on GW Pharma (NASDAQ: GWPH) and raised its price target to $152.00 (from $149.00).
For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.
Shares of GW Pharma closed at $88.49 yesterday.
...
More
June 27, 2016 9:52 AM EDT
Leerink Partners analyst Paul Matteis reiterated an Outperform rating and raised his price target on GW Pharma (NASDAQ: GWPH) to $138.00 (from $130.00) after the company announced positive results for its 1st Phase 3 study for Epidiolex in Lennox-Gastaut Syndrome (LGS).
"... our view remains positive after the... More
June 27, 2016 7:03 AM EDT
GW Pharmaceuticals plc (Nasdaq: GWPH) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added as an adjunct to the patients current treatment, achieved the primary endpoint of a significant reduction in the monthly frequency of drop seizures assessed over the entire 14-week treatment period compared with placebo (p=0.0135). This trial follows the announcement in March 2016 of positive results in a... More
